Your search returned 5 results.

Results
	1.	Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. MedStar authors: Swain, Sandra M PMID: 26545405 Year: 2016 Citation: Cancer Epidemiology, Biomarkers & Prevention. 25(1):51-9, 2016 Jan. Institution: Washington Cancer Institute Medline publication type: Journal Article Multicenter Study Randomized Controlled Trial Form of publication: Journal Article All authors: Anderson SJ, Cecchini RS, Costantino JP, Geyer CE Jr, Jeong JH, Lembersky BC, Paterson AH, Rastogi P, Romond EH, Swain SM, Tang G, Wolmark N DOI: http://dx.doi.org/10.1158/1055-9965.EPI-15-0334-T Add to cart (remove)
	2.	The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. MedStar authors: Swain, Sandra M PMID: 26759246 Year: 2016 Citation: Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan. Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Amiri-Kordestani L, Chavez KJ, Conway CM, Dine JL, Greer YE, Hewitt SM, Lipkowitz S, Merchant AS, O'Sullivan CC, Sinclair S, Steinberg SM, Stone B, Swain SM, Voeller D Add to cart (remove)
	3.	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors: Swain, Sandra M PMID: 24869931 Year: 2014 Citation: Oncologist. 19(7):693-701, 2014 Jul. Institution: Washington Cancer Institute Form of publication: Journal Article All authors: Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2014-0033 Add to cart (remove)
	4.	NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. MedStar authors: Swain, Sandra M PMID: 32371537 Year: 2020 Citation: Clinical Cancer Research. 26(16):4233-4241, 2020 08 15. Institution: MedStar Health Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Bandos H, Brauer HA, Geyer CE Jr, Goerlitz DS, Harris BT, Lucas PC, Mamounas EP, Rastogi P, Ren Y, Robidoux A, Swain SM, Tang G, Wolmark N DOI: https://dx.doi.org/10.1158/1078-0432.CCR-20-0152 Add to cart (remove)
	5.	Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors: Swain, Sandra M PMID: 27693116 Year: 2017 Citation: Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N DOI: https://dx.doi.org/10.1016/j.clbc.2016.07.008 Add to cart (remove)

Powered by Koha